RadioMedix and Curium announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has granted transitional pass-through status to Detectnet PET diagnostic radiopharmaceutical copper-64 (Cu-64) DOTATATE.
Detectnet is a PET radiopharmaceutical indicated for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients. The tracer received U.S. Food and Drug Administration clearance earlier this year.
The CMS coding move should make it easier for Detectnet users to receive Medicare reimbursement for procedures, the companies said.
Effective January 1, 2021, Detectnet's descriptor will be: Copper Cu-64, dotatate, diagnostic, 1 millicurie. Code C9068 will be used to bill Detectnet for Medicare patients seen in outpatient departments at hospitals.
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
